Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: News Bites Pty Limited
$5.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd receives USFDA approval for Repaglinide Tablets


Thursday, 23 Jan 2014 03:00am EST 

Aurobindo Pharma Ltd:Receives final approval from the US Food & Drug Administration to manufacture and market Repaglinide Tablets USP 0.5mg, 1mg and 2mg.Says product is ready for launch.Says Repaglinide Tablets USP 0.5mg, 1mg and 2mg are the generic equivalent of Novo Nordisk Inc’s Prandin Tablets USP 0.5mg, 1mg and 2mg and indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Says market size of the product is estimated to be $ 274 mln for the twelve months ending Nov. 2013 according to IMS.Says it has a total of 189 ANDA approvals (164 Final approvals including 7 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA. 

Related Company News

Company Quote

551.0
3.2 +0.58%
6:29am EDT